AFP Clinical Answers

Abdominal Aortic Aneurysm, Migraines in Children, Mucolytics for COPD, Paget Disease, ARDS

 

Am Fam Physician. 2021 Jun 1;103(11):659.

In what population is screening for abdominal aortic aneurysm appropriate based on USPSTF recommendations?

The U.S. Preventive Services Task Force (USPSTF) recommends one-time screening for abdominal aortic aneurysm (AAA) with ultrasonography in men 65 to 75 years of age who have ever smoked. The USPSTF recommends that clinicians selectively offer AAA screening with ultrasonography in men 65 to 75 years of age who have never smoked instead of routinely screening all men in this group. The USPSTF recommends against screening women who have never smoked and have no family history of AAA. The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for AAA in women 65 to 75 years of age who have ever smoked or have a family history of AAA.

https://www.aafp.org/afp/2020/0515/p621.html

What are the first-line medications used to treat acute migraines in children?

First-line acute migraine treatment in children is ibuprofen; adolescents may benefit from sumatriptan/naproxen (Treximet) tablets, zolmitriptan (Zomig) nasal spray, sumatriptan (Imitrex) nasal spray, rizatriptan (Maxalt), or almotriptan (Axert).

https://www.aafp.org/afp/2020/0501/p569.html

Are oral mucolytics effective at reducing the number of acute exacerbations, days of disability, and hospital admissions in patients with chronic bronchitis or COPD?

Oral mucolytic agents may reduce the number of acute exacerbations in patients with chronic bronchitis or chronic obstructive pulmonary disease (COPD; number needed to treat [NNT] = 8, over an average of nine months). Although mucolytics do not appear to impact lung function or quality of life, they are associated with a small reduction in days of disability per month (mean difference = −0.43 days) and decreased hospital admissions (NNT for 17 months = 19). Mucolytics are not associated with an increase in adverse effects.

https://www.aafp.org/afp/2020/0701/p16.html

What medication is recommended for the treatment

 

 

Copyright © 2021 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions

CME Quiz

More in AFP


Editor's Collections


More in Pubmed

MOST RECENT ISSUE


Oct 2021

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article